Bearish flow noted in Biogen (BIIB) with 1,136 puts trading, or 1.1x expected. Most active are Apr-25 160 puts and 11/29 weekly 162.5 calls, ...

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The company’s shares opened today at $159.99. Don't Miss our ...

Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

Needham sees no near-term catalysts for Biogen The brokerage said it sees Leqembi’s sales projection “likely to continue to be a slow grind, rather than see an inflection point” and said it ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Sage to abandon development of neurological disorder drug after multiple failures November 20, 2024 The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

Biogen Pharmachem Industries Limited is an India-based company, which is not engaged in any activity. The Company is looking for the right opportunity to make the Company operational. What is the ...

Beyond logos, create business cards, social media kits, favicons, and more. Download high-resolution PNG, JPEG, and vector files, and get brand guidelines for fonts and colors. Make unlimited changes ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.